UNI-EN 5:MINUTES OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 5 | / | 2011 | | ||||||
Date of issue: | 2011-12-02 | ||||||||||
Short name of the issuer | |||||||||||
SOPHARMA AD | |||||||||||
Subject | |||||||||||
MINUTES OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS | |||||||||||
Official market - legal basis | |||||||||||
Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne | |||||||||||
Unofficial market - legal basis | |||||||||||
Contents of the report: | |||||||||||
The Board of Directors of SOPHARMA AD (the “Company") hereby publish the minutes of the Extraordinary General Meeting of the Company’s Shareholders held on 30 November 2011. | |||||||||||
Annexes | |||||||||||
File | Description | ||||||||||
Sopharma_minutes of the extraordinary general meeting of shareholders.pdf Sopharma_minutes of the extraordinary general meeting of shareholders.pdf | Minutes of the extraordinary general meeting of shareholders |
SOPHARMA AD | |||||||||||||
(fullname of the issuer) | |||||||||||||
SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
(short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
1220 | Sofia | ||||||||||||
(post code) | (city) | ||||||||||||
IlienskoShosse | 16 | ||||||||||||
(street) | (number) | ||||||||||||
+359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
(phone number) | (fax) | ||||||||||||
(e-mail) | (web site) | ||||||||||||
nd | nd | ||||||||||||
(NIP) | (REGON) |
SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
Date | Name | Position / Function | Signature | ||
2011-12-02 | Ognian Donev | Chairman of the Board of Directors |
Cena akcji Sopharma
Cena akcji Sopharma w momencie publikacji komunikatu to None PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.